新型抗肿瘤药物对肺动脉高压的差异化作用研究进展  

Research progress on the differential effects of novel anti-tumor drugs on pulmonary hypertension

作　　者：张从金 李卫平 钱火连 钱青 王强 ZHANG Congjin;LI Weiping;QIAN Huolian;QIAN Qing;WANG Qiang(Dept.of Pharmacy,the Second Affiliated Hospital of Army Medical University,Chongqing 400037,China)

机构地区：[1]陆军军医大学第二附属医院药剂科,重庆400037

出　　处：《中国药房》2025年第6期758-763,共6页China Pharmacy

基　　金：重庆市自然科学基金项目(No.CSTB2023NSCQZDX0012)。

摘　　要：肺动脉高压(PH)是一种严重而罕见的慢性心肺疾病,现有的血管扩张疗法只能改善症状,不能靶向或从根本上逆转疾病,且长期预后不佳。近年来研究发现,部分新型抗肿瘤药物(NADs)能够减轻PH症状,如伊马替尼、吉非替尼、索拉非尼、奥拉帕利、哌柏西利、依维莫司、利妥昔单抗等;但又有部分NADs会诱发PH或使PH症状加重,如达沙替尼、洛拉替尼、卡非佐米、贝伐珠单抗、曲妥珠单抗、纳武利尤单抗等;而拉帕替尼、芦可替尼、硼替佐米等对PH的作用存在争议。临床在使用NADs治疗PH时应进行个体化用药,并注意密切监测。Pulmonary hypertension(PH)is a severe and rare chronic cardiopulmonary disorder for which existing vasodilator therapies can only alleviate symptoms,rather than target or fundamentally reverse the disease.Additionally,the long-term prognosis remains poor.Recent studies have found that some novel anti-tumor drugs(NADs)can relieve PH,such as imatinib,gefitinib,sorafenib,olaparib,piperacillin,everolimus,rituximab,etc.However,some NADs can induce PH or exacerbate its symptoms,including dasatinib,lorlatinib,carfilzomib,bevacizumab,trastuzumab,nivolumab,etc.The effects of lapatinib,ruxolitinib,and bortezomib on PAH are controversial.Individualized medication should be adopted in clinical practice when using NADs for treatment,with close monitoring being essential.

关 键 词：新型抗肿瘤药物 肺动脉高压 伊马替尼 纳武利尤单抗 

分 类 号：R979.1[医药卫生—药品]